The Board of Directors of Ranbaxy Laboratories at their recently held meeting, took on record the unaudited results for the quarter and half year ended September 30, 2014 (Q2’15 and H1’15 respectively).
Under the consolidated financial performance for the quarter ended September 30, 2014 (Q2’15), sales were posted at Rs 32,180 million [Jul’13-Sep’13: Sales Rs 27,502 million]. Sales were higher primarily due to exclusivity sales of Valsartan in the US during the quarter. Earnings before interest, tax, depreciation and amortization (EBITDA) was Rs 8,071 million.
Under the consolidated financial performance for YTD ended September 30, 2014 (H1’15), sales were at Rs 55,902 million [Apr’13-Sep’13: Sales Rs 53,341 million]. EBITDA was at Rs 10,450 million. Net profit after tax, minority interest and share in loss of associate was at Rs 4,778 million during the quarter.
Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy, said, “During the quarter, growth in base business was driven by India and Western Europe. In the US, we successfully launched Valsartan with 180 days exclusivity. Our focus continues to be on creating brands and providing differentiated products as future growth drivers”.
EP News Bureau– Mumbai
